1. Clinical Overview

Molecule: Short tripeptide Glu–Asp–Arg (EDR-peptide), isolated from the pineal gland. Part of the cytomedin / short-peptide bioregulator family.

Classification: Neuroprotective peptide • Epigenetic regulatory • Cognitive/memory enhancer • Anti-inflammatory neuroregulator • Mitochondrial-support • Anti-aging bioregulator

Key Distinctions: Acts directly at nuclear DNA regulation level, modulates gene expression related to brain aging, potent antioxidant & mitochondrial-stabilizing effects, benefits in older adults and neurodegenerative conditions. Widely used in Russian/Eastern European peptide medicine.

2. Mechanisms of Action

2.1 Epigenetic Regulation

Modulates DNA methylation, histone acetylation, microRNA expression. Improved youthful neuronal gene expression, slowed epigenetic aging, increased neurotrophic signaling.

2.2 Mitochondrial Protection

Stabilizes mitochondrial membranes, reduces ROS, prevents mtDNA oxidative damage, enhances ATP production. Supports cognition, memory, cellular longevity.

2.3 Anti-Apoptotic (Neuroprotection)

Inhibits caspase-3, cytokine-induced apoptosis, excitotoxic death. Relevant in brain aging, stroke recovery (adjunctive), TBI (research), neurodegeneration.

2.4 Antioxidant & Anti-Inflammatory

Reduces IL-6, IL-1β, TNF-α, NF-κB. Useful for cognitive fog, chronic inflammation, age-related decline.

2.5 Neuroendocrine & Circadian

Pineal origin supports melatonin synthesis balance, circadian rhythm restoration, neuroendocrine resilience.

3. Evidence-Supported Applications

3.1 Age-Related Cognitive Decline

Improved memory recall, processing speed, executive function, reduced mental fatigue. MCI and age-related memory loss.

3.2 Neuroprotection (Stress/Injury/Ischemia)

TBI recovery, stroke rehabilitation, chronic stress neuronal depletion, neuroinflammatory states (research settings).

3.3 Mitochondrial Dysfunction

Brain fog, chronic fatigue, post-viral cognitive impairment, early neurodegeneration. Pairs well with SS-31 and NAD+.

3.4 Mood & Resilience

Reduced anxiety, improved sleep, emotional stability, stress resilience. Mild but clinically relevant.

3.5 Anti-Aging / Longevity

Reduces epigenetic aging of neural tissue, cognitive longevity, whole-brain mitochondrial function. Often in annual peptide rotations.

4. Administration & Protocols

4.1 SC Injection (Preferred)

Standard Cognitive/Anti-Aging: 100–300 mcg SC once daily
Neuroprotective/Injury: 300–500 mcg SC daily × 10–20 days, then maintenance
Maintenance: 100–200 mcg SC 2–3×/week

4.2 Oral Bioregulator

Standard: 10–20 mg daily | Enhanced: 20–40 mg daily
Cycle: 10 days on / 20 days off, repeat

Duration

Cognitive decline: 30–60 days. Anti-aging: 30-day cycle every 3–6 months. TBI/Stroke: 30–45 days (research context).

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ SS-31: Mitochondrial repair + neuroprotection — most potent energetic synergy
+ MOTS-c: Cellular metabolism + brain mitochondrial efficiency
+ NAD+: Deep neuronal energy production support
+ Epitalon: Pineal peptide synergy — circadian normalization, anti-aging, neuroendocrine stability
+ DSIP: Sleep regulation — REM stability, deep sleep, cognitive restoration

6. Clinical Decision Trees

Decision Tree 1 — Is Pinealon Indicated?

Age-related memory decline? → YES

Mitochondrial dysfunction / brain fog? → YES

Post-stress neurocognitive fatigue? → YES

TBI or ischemic recovery? → YES (research context)

Anti-aging / longevity? → YES

Primary depression? → Adjunctive only

Decision Tree 2 — Route Selection

Rapid neurological effect? → SC injection

Long-term maintenance? → Oral bioregulator capsules

Mitochondrial synergy? → Pinealon + SS-31

Sleep disturbance? → Pinealon + DSIP

7. Integrated Archetypes

A — Cognitive Enhancement

Pinealon 100–300 mcg SC daily + NAD+ weekly + SS-31 + RECOVER™ AM
Outcome: Focus, clarity, memory, cognitive stamina.

B — Neuroprotection / Stress Burnout

Pinealon 300–500 mcg SC + MOTS-c weekly + DSIP nightly + Omega-3 DHA
Outcome: Brain restoration, anti-inflammatory renewal.

C — Longevity / Anti-Aging Brain

Pinealon daily × 20–30 days + Epitalon nightly + NAD+ IV weekly + Glutathione
Outcome: Epigenetic rejuvenation, improved brain function.

D — Mitochondrial Enhancement

Pinealon daily + SS-31 + CoQ10 + PQQ + MOTS-c
Outcome: Sharper cognition, higher energy output.

8. Expected Timeline

Week 1: Improved clarity, calmer mood
Week 2–3: Better sleep, enhanced memory recall
Week 3–6: Strong cognitive gains, neuroenergy improvement
Long-term: Epigenetic & mitochondrial resilience

9. Contraindications

Absolute

Pregnancy / Breastfeeding
Active cancer (growth signaling precaution)

Relative

Severe psychiatric disorders
Uncontrolled epilepsy
Autoimmune neurologic diseases (case-by-case)

10. Adverse Effects

Very well tolerated. Possible: mild headache, transient fatigue, restlessness (rare), slight BP variation (rare). No known major adverse effects.

11. Monitoring

Cognitive function testing
Sleep quality
Mood stability
Mitochondrial biomarkers (optional)
Memory recall assessments
HRV / stress markers (if available)

Legal Disclaimer

This document is provided solely for educational and informational purposes. Pinealon and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Pinealon

Foundational Discovery

1. Khavinson, V. K., & Lin’kova, N. S. Short peptides regulate gene expression: Pinealon. Bull Exp Biol Med, 149(4), 473–476 (2010).

2. Khavinson, V. K., et al. Neuroprotective peptides: geroprotective action. Adv Gerontol, 28(1), 47–55 (2018).

3. Khavinson, V. K., et al. Tripeptide Glu-Asp-Gly on chromatin. Biochemistry (Moscow), 77(7), 725–732 (2012).

Neuroprotection & Cognition

4. Anisimov, V. N., et al. Memory and learning in aging rodents. Neurosci Behav Physiol, 41(1), 21–28 (2011).

5. Polyakova, V. O., et al. Neuroprotective effects against oxidative stress. Neurochem J, 6(3), 228–235 (2012).

6. Shataeva, L. K., et al. Prevents neuronal apoptosis in hypoxia. Neurosci Lett, 510(1), 29–34 (2012).

7. Arutjunyan, A. V., & Vetvicka, V. Mitochondrial protection under oxidative load. Biomed Pharmacother, 68(3), 343–349 (2014).

Epigenetic & Gene Expression

8. Ashapkin, V. V., et al. Short peptides restore epigenetic regulation. Epigenomics, 7(1), 129–141 (2015).

9. Khavinson, V. K., et al. Gene expression in stress resistance. Mol Biol Reports, 40(6), 3719–3725 (2013).

10. Khavinson, V. K., et al. Genome-wide modulation in neurons. Bull Exp Biol Med, 152(5), 632–636 (2011).

Stroke & Ischemia

11. Mikhailova, N., et al. Recovery after experimental stroke. J Stroke Cerebrovasc Dis, 22(3), e269–e276 (2013).

12. Drobyshev, E. J., et al. Tripeptide neuroprotection in hypoxia-ischemia. Neurosci Behav Physiol, 45(8), 958–965 (2015).

13. Gorban, N. A., et al. Post-stroke cognitive/motor recovery. Restor Neurol Neurosci, 29(6), 507–516 (2011).

Metabolic & Oxidative Stress

14. Arutyunyan, A. V., et al. Antioxidant activity in systemic stress. Bull Exp Biol Med, 153(3), 325–329 (2012).

15. Sukhikh, G. T., et al. Mitochondrial redox potential. Biochemistry (Moscow), 81(10), 1233–1242 (2016).

Immune & Anti-Inflammatory

16. Vetvicka, V., & Vetvickova, J. Peptide bioregulators as immune modulators. Int Immunopharmacol, 22(2), 364–372 (2014).

17. Kuznik, B. I., et al. Immune normalization in aging. J Gerontol Geriatr Res, 6(5), 411–418 (2017).

Human Clinical

18. Korkushko, O. V., et al. Clinical evaluation for cognitive decline. Clin Interv Aging, 8, 1101–1107 (2013).

19. Khavinson, V. K., et al. Neuroprotective in MCI. Adv Gerontol, 27(3), 487–494 (2014).

20. Miasoedov, N. F., et al. Short peptides and neuroendocrine aging. Neurochem J, 9(4), 238–245 (2015).

Aging & Longevity

21. Khavinson, V. K., et al. Geroprotective effects in aging models. Rejuvenation Res, 14(2), 215–223 (2011).

22. Arutjunyan, A., et al. Adaptation and oxidative aging markers. Gerontology, 60(4), 302–311 (2014).

23. Koltover, V. K., et al. DNA/protein synthesis stabilization. Biogerontology, 17(2), 267–278 (2016).

Safety & Toxicology

24. Ashapkin, V. V., et al. Peptide bioregulator toxicity profiles. Cell Tissue Biol, 10(6), 469–478 (2016).

25. Khavinson, V. K., & Kuznik, B. I. Long-term safety in humans. Bull Exp Biol Med, 159(2), 225–232 (2015).

26. Shataeva, L. K., et al. Safety in neuroprotective dosing. Exp Biol Med, 237(9), 1052–1059 (2012).

Pinealon (EDR Tripeptide)